T cell therapies for human polyomavirus diseases

Cytotherapy

Volumn 19, Issue 11, 2017, Pages 1302-1316

  Davies, Sarah I ^a,b   Muranski, Pawel ^a,c  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^b GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^c Department of Medicine   (United States)

Author keywords

BK polyomavirus; cellular immunotherapy; hemorrhagic cystitis; JC polyomavirus; Merkel cell carcinoma; Merkel cell polyomavirus

Indexed keywords

ALEMTUZUMAB; CIRCULAR DNA; IBRUTINIB; IMMUNOSUPPRESSIVE AGENT; NATALIZUMAB; ONCOPROTEIN; RITUXIMAB; VIRAL PROTEIN;

BK VIRUS; BK VIRUS INFECTION; CELL SPECIFICITY; CELL THERAPY; CELLULAR IMMUNITY; CLINICAL TRIAL (TOPIC); HEMORRHAGIC CYSTITIS; HOST CELL; HUMAN; HUMORAL IMMUNITY; IMMUNOTHERAPY; INFECTION; INNATE IMMUNITY; JC VIRUS; KIDNEY DISEASE; MERKEL CELL CARCINOMA; MERKEL CELL POLYOMAVIRUS; POLYOMAVIRUS; POLYOMAVIRUS INFECTION; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; REVIEW; T LYMPHOCYTE; VIRUS CELL INTERACTION; VIRUS IMMUNITY; VIRUS REPLICATION; VIRUS STRAIN; ADOPTIVE IMMUNOTHERAPY; CELL TRANSPLANTATION; EPSTEIN BARR VIRUS; IMMUNOCOMPROMISED PATIENT; IMMUNOLOGY; PATHOGENICITY; PROCEDURES; TRANSPLANTATION; VIROLOGY;

CELL TRANSPLANTATION; HERPESVIRUS 4, HUMAN; HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOTHERAPY, ADOPTIVE; KIDNEY DISEASES; POLYOMAVIRUS; POLYOMAVIRUS INFECTIONS; T-LYMPHOCYTES;

EID: 85029510066     PISSN: 14653249     EISSN: 14772566     Source Type: Journal    
DOI: 10.1016/j.jcyt.2017.08.011     Document Type: Review

References (161)

1. White, M.K., Gordon, J., Khalili, K., The rapidly expanding family of human polyomaviruses: recent developments in understanding their life cycle and role in human pathology. PLoS Pathog, 9(3), 2013 e1003206.
2. Antonsson, A., Green, A.C., Mallitt, K.A., O'Rourke, P.K., Pawlita, M., Waterboer, T., et al. Prevalence and stability of antibodies to the BK and JC polyomaviruses: a long-term longitudinal study of Australians. J Gen Virol 91:Pt 7 (2010), 1849–1853.
3. Sroller, V., Hamsikova, E., Ludvikova, V., Vochozkova, P., Kojzarova, M., Fraiberk, M., et al. Seroprevalence rates of BKV, JCV, and MCPyV polyomaviruses in the general Czech Republic population. J Med Virol 86:9 (2014), 1560–1568.
4. Knowles, W.A., Discovery and epidemiology of the human polyomaviruses BK virus (BKV) and JC virus (JCV). Adv Exp Med Biol 577 (2006), 19–45.
5. Feng, H., Shuda, M., Chang, Y., Moore, P.S., Clonal integration of a polyomavirus in human Merkel cell carcinoma. Science 319:5866 (2008), 1096–1100.
6. DeCaprio, J.A., Garcea, R.L., A cornucopia of human polyomaviruses. Nat Rev Micro 11:4 (2013), 264–276.
7. Jiang, M., Abend, J.R., Johnson, S.F., Imperiale, M.J., The role of polyomaviruses in human disease. Virology 384:2 (2009), 266–273.
8. Arora, R., Chang, Y., Moore, P.S., MCV and Merkel cell carcinoma: a molecular success story. Curr Opin Virol 2:4 (2012), 489–498.
9. Delbue, S., Comar, M., Ferrante, P., Review on the role of the human Polyomavirus JC in the development of tumors. Infect Agent Cancer, 12, 2017, 10.
10. Delbue, S., Ferrante, P., Provenzano, M., Polyomavirus BK and prostate cancer: an unworthy scientific effort?. Oncoscience 1:4 (2014), 296–303.
11. Egli, A., Infanti, L., Dumoulin, A., Buser, A., Samaridis, J., Stebler, C., et al. Prevalence of Polyomavirus BK and JC Infection and Replication in 400 Healthy Blood Donors. J Infect Dis 199:6 (2009), 837–846.
12. Elsner, C., Dörries, K., Evidence of human polyomavirus BK and JC infection in normal brain tissue. Virology 191:1 (1992), 72–80.
13. Arthur, R.R., Shah, K.V., Baust, S.J., Santos, G.W., Saral, R., Association of BK viruria with hemorrhagic cystitis in recipients of bone-marrow transplants. N Engl J Med 315:4 (1986), 230–234.
14. Gilis, L., Morisset, S., Billaud, G., Ducastelle-Lepretre, S., Labussiere-Wallet, H., Nicolini, F.E., et al. High burden of BK virus-associated hemorrhagic cystitis in patients undergoing allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 49:5 (2014), 664–670.
15. Ambalathingal, G.R., Francis, R.S., Smyth, M.J., Smith, C., Khanna, R., Polyomavirus, B.K., Clinical aspects, immune regulation, and emerging therapies. Clin Microbiol Rev 30:2 (2017), 503–528.
16. Dall, A., Hariharan, S., BK virus nephritis after renal transplantation. Clin J Am Soc Nephrol 3:Suppl. 2 (2008), S68–75.
17. Hirsch, H.H., Knowles, W., Dickenmann, M., Passweg, J., Klimkait, T., Mihatsch, M.J., et al. Prospective study of polyomavirus type BK replication and nephropathy in renal-transplant recipients. N Engl J Med 347:7 (2002), 488–496.
18. Hirsch, H.H., Vincenti, F., Friman, S., Tuncer, M., Citterio, F., Wiecek, A., et al. Polyomavirus BK replication in de novo kidney transplant patients receiving tacrolimus or cyclosporine: a prospective, randomized, multicenter study. Am J Transplant 13:1 (2013), 136–145.
19. Ramos, E., Drachenberg, C.B., Wali, R., Hirsch, H.H., The decade of polyomavirus BK-associated nephropathy: state of affairs. Transplantation 87:5 (2009), 621–630.
20. Gard, L., van Doesum, W., Niesters, H.G.M., van Son, W.J., Diepstra, A., Stegeman, C.A., et al. A delicate balance between rejection and BK polyomavirus associated nephropathy; A retrospective cohort study in renal transplant recipients. PLoS ONE, 12(6), 2017 e0178801.
21. Lamarche, C., Orio, J., Collette, S., Senecal, L., Hebert, M.J., Renoult, E., et al. BK polyomavirus and the transplanted kidney: immunopathology and therapeutic approaches. Transplantation 100:11 (2016), 2276–2287.
22. Schaub, S., Hirsch, H.H., Dickenmann, M., Steiger, J., Mihatsch, M.J., Hopfer, H., et al. Reducing immunosuppression preserves allograft function in presumptive and definitive polyomavirus-associated nephropathy. Am J Transplant 10:12 (2010), 2615–2623.
23. Astrom, K.E., Mancall, E.L., Richardson, E.P. Jr, Progressive multifocal leuko-encephalopathy; a hitherto unrecognized complication of chronic lymphatic leukaemia and Hodgkin's disease. Brain 81:1 (1958), 93–111.
24. Khanna, N., Elzi, L., Mueller, N.J., Garzoni, C., Cavassini, M., Fux, C.A., et al. Incidence and outcome of progressive multifocal leukoencephalopathy over 20 years of the Swiss HIV Cohort Study. Clin Infect Dis 48:10 (2009), 1459–1466.
25. Bowen, L.N., Smith, B., Reich, D., Quezado, M., Nath, A., HIV-associated opportunistic CNS infections: pathophysiology, diagnosis and treatment. Nat Rev Neurol 12:11 (2016), 662–674.
26. Clifford, D.B., De Luca, A., Simpson, D.M., Arendt, G., Giovannoni, G., Nath, A., Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases. Lancet Neurol 9:4 (2010), 438–446.
27. Langer-Gould, A., Atlas, S.W., Green, A.J., Bollen, A.W., Pelletier, D., Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med 353:4 (2005), 375–381.
28. Van Assche, G., Van Ranst, M., Sciot, R., Dubois, B., Vermeire, S., Noman, M., et al. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. N Engl J Med 353:4 (2005), 362–368.
29. Tan, I.L., McArthur, J.C., Clifford, D.B., Major, E.O., Nath, A., Immune reconstitution inflammatory syndrome in natalizumab-associated PML. Neurology 77:11 (2011), 1061–1067.
30. Carson, K.R., Evens, A.M., Richey, E.A., Habermann, T.M., Focosi, D., Seymour, J.F., et al. Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood 113:20 (2009), 4834–4840.
31. Molloy, E.S., Calabrese, L.H., Progressive multifocal leukoencephalopathy in patients with rheumatic diseases: are patients with systemic lupus erythematosus at particular risk?. Autoimmun Rev 8:2 (2008), 144–146.
32. Lutz, M., Schulze, A.B., Rebber, E., Wiebe, S., Zoubi, T., Grauer, O.M., et al. Progressive multifocal leukoencephalopathy after ibrutinib therapy for chronic lymphocytic leukemia. Cancer Res Treat 49:2 (2017), 548–552.
33. Raisch, D.W., Rafi, J.A., Chen, C., Bennett, C.L., Detection of cases of progressive multifocal leukoencephalopathy associated with new biologicals and targeted cancer therapies from the FDA's adverse event reporting system. Expert Opin Drug Saf 15:8 (2016), 1003–1011.
34. Misbah, S.A., Progressive multi-focal leucoencephalopathy—driven from rarity to clinical mainstream by iatrogenic immunodeficiency. Clin Exp Immunol 188:3 (2017), 342–352.
35. Mateen, F.J., Muralidharan, R., Carone, M., van de Beek, D., Harrison, D.M., Aksamit, A.J., et al. Progressive multifocal leukoencephalopathy in transplant recipients. Ann Neurol 70:2 (2011), 305–322.
36. Garcia-Suarez, J., de Miguel, D., Krsnik, I., Banas, H., Arribas, I., Burgaleta, C., Changes in the natural history of progressive multifocal leukoencephalopathy in HIV-negative lymphoproliferative disorders: impact of novel therapies. Am J Hematol 80:4 (2005), 271–281.
37. Viscidi, R.P., Rollison, D.E., Sondak, V.K., Silver, B., Messina, J.L., Giuliano, A.R., et al. Age-specific seroprevalence of Merkel cell polyomavirus, BK virus, and JC virus. Clin Vaccine Immunol 18:10 (2011), 1737–1743.
38. Zhang, C., Liu, F., He, Z., Deng, Q., Pan, Y., Liu, Y., et al. Seroprevalence of Merkel cell polyomavirus in the general rural population of Anyang, China. PLoS ONE, 9(9), 2014, e106430.
39. Pancaldi, C., Corazzari, V., Maniero, S., Mazzoni, E., Comar, M., Martini, F., et al. Merkel cell polyomavirus DNA sequences in the buffy coats of healthy blood donors. Blood 117:26 (2011), 7099–7101.
40. Signorini, L., Belingheri, M., Ambrogi, F., Pagani, E., Binda, S., Ticozzi, R., et al. High frequency of Merkel cell polyomavirus DNA in the urine of kidney transplant recipients and healthy controls. J Clin Virol 61:4 (2014), 565–570.
41. Miller, R.W., Rabkin, C.S., Merkel cell carcinoma and melanoma: etiological similarities and differences. Cancer Epidemiol Biomarkers Prev 8:2 (1999), 153–158.
42. Fitzgerald, T.L., Dennis, S., Kachare, S.D., Vohra, N.A., Wong, J.H., Zervos, E.E., Dramatic increase in the incidence and mortality from merkel cell carcinoma in the United States. Am Surg 81:8 (2015), 802–806.
43. Afanasiev, O.K., Yelistratova, L., Miller, N., Nagase, K., Paulson, K., Iyer, J.G., et al. Merkel polyomavirus-specific T cells fluctuate with merkel cell carcinoma burden and express therapeutically targetable PD-1 and Tim-3 exhaustion markers. Clin Cancer Res 19:19 (2013), 5351–5360.
44. Rodig, S.J., Cheng, J., Wardzala, J., DoRosario, A., Scanlon, J.J., Laga, A.C., et al. Improved detection suggests all Merkel cell carcinomas harbor Merkel polyomavirus. J Clin Invest 122:12 (2012), 4645–4653.
45. Heath, M., Jaimes, N., Lemos, B., Mostaghimi, A., Wang, L.C., Penas, P.F., et al. Clinical characteristics of Merkel cell carcinoma at diagnosis in 195 patients: the AEIOU features. J Am Acad Dermatol 58:3 (2008), 375–381.
46. Buck, C.B., Van Doorslaer, K., Peretti, A., Geoghegan, E.M., Tisza, M.J., An, P., et al. The ancient evolutionary history of polyomaviruses. PLoS Pathog, 12(4), 2016 e1005574.
47. Sharma, P.M., Gupta, G., Vats, A., Shapiro, R., Randhawa, P.S., Polyomavirus, B.K., non-coding control region rearrangements in health and disease. J Med Virol 79:8 (2007), 1199–1207.
48. Gosert, R., Kardas, P., Major, E.O., Hirsch, H.H., Rearranged JC virus noncoding control regions found in progressive multifocal leukoencephalopathy patient samples increase virus early gene expression and replication rate. J Virol 84:20 (2010), 10448–10456.
49. Lynch, K.J., Frisque, R.J., Identification of critical elements within the JC virus DNA replication origin. J Virol 64:12 (1990), 5812–5822.
50. DeCaprio, J.A., Garcea, R.L., A cornucopia of human polyomaviruses. Nat Rev Microbiol 11:4 (2013), 264–276.
51. Teunissen, E.A., de Raad, M., Mastrobattista, E., Production and biomedical applications of virus-like particles derived from polyomaviruses. J Control Release 172:1 (2013), 305–321.
52. An, P., Saenz Robles, M.T., Pipas, J.M., Large T antigens of polyomaviruses: amazing molecular machines. Annu Rev Microbiol 66 (2012), 213–236.
53. Randhawa, P., Viscidi, R., Carter, J.J., Galloway, D.A., Culp, T.D., Huang, C., et al. Identification of species-specific and cross-reactive epitopes in human polyomavirus capsids using monoclonal antibodies. J Gen Virol 90:Pt 3 (2009), 634–639.
54. Chen, Y., Trofe, J., Gordon, J., Autissier, P., Woodle, E.S., Koralnik, I.J., BKV and JCV large T antigen-specific CD8+ T cell response in HLA A*0201+ kidney transplant recipients with polyomavirus nephropathy and patients with progressive multifocal leukoencephalopathy. J Clin Virol 42:2 (2008), 198–202.
55. Cioni, M., Leboeuf, C., Comoli, P., Ginevri, F., Hirsch, H.H., Characterization of Immunodominant BK Polyomavirus 9mer Epitope T Cell Responses. Am J Transplant 16:4 (2016), 1193–1206.
56. Jelcic, I., Aly, L., Binder, T.M., Jelcic, I., Bofill-Mas, S., Planas, R., et al. T cell epitope mapping of JC polyoma virus-encoded proteome reveals reduced T cell responses in HLA-DRB1*04:01+ donors. J Virol 87:6 (2013), 3393–3408.
57. Li, J., Melenhorst, J., Hensel, N., Rezvani, K., Sconocchia, G., Kilical, Y., et al. T-cell responses to peptide fragments of the BK virus T antigen: implications for cross-reactivity of immune response to JC virus. J Gen Virol 87:Pt 10 (2006), 2951–2960.
58. Mani, J., Wang, L., Huckelhoven, A.G., Schmitt, A., Gedvilaite, A., Jin, N., et al. Definition and characterization of novel HLA-*A02-restricted CD8+ T cell epitopes derived from JCV polyomavirus with clinical relevance. Oncotarget 8:2 (2017), 2485–2500.
59. Ramaswami, B., Popescu, I., Macedo, C., Metes, D., Bueno, M., Zeevi, A., et al. HLA-A01-, -A03-, and -A024-binding nanomeric epitopes in polyomavirus BK large T antigen. Hum Immunol 70:9 (2009), 722–728.
60. Sharma, M.C., Zhou, W., Martinez, J., Krymskaya, L., Srivastava, T., Haq, W., et al. Cross-reactive CTL recognizing two HLA-A*02-restricted epitopes within the BK virus and JC virus VP1 polypeptides are frequent in immunocompetent individuals. Virology 350:1 (2006), 128–136.
61. Trowbridge, P.W., Frisque, R.J., Identification of three new JC virus proteins generated by alternative splicing of the early viral mRNA. J Neurovirol 1:2 (1995), 195–206.
62. Bollag, B., Kilpatrick, L.H., Tyagarajan, S.K., Tevethia, M.J., Frisque, R.J., JC virus T’135, T’136 and T’165 proteins interact with cellular p107 and p130 in vivo and influence viral transformation potential. J Neurovirol 12:6 (2006), 428–442.
63. Gorelik, L., Reid, C., Testa, M., Brickelmaier, M., Bossolasco, S., Pazzi, A., et al. Progressive multifocal leukoencephalopathy (PML) development is associated with mutations in JC virus capsid protein VP1 that change its receptor specificity. J Infect Dis 204:1 (2011), 103–114.
64. Gosert, R., Rinaldo, C.H., Funk, G.A., Egli, A., Ramos, E., Drachenberg, C.B., et al. Polyomavirus BK with rearranged noncoding control region emerge in vivo in renal transplant patients and increase viral replication and cytopathology. J Exp Med 205:4 (2008), 841–852.
65. Pfister, L.A., Letvin, N.L., Koralnik, I.J., JC virus regulatory region tandem repeats in plasma and central nervous system isolates correlate with poor clinical outcome in patients with progressive multifocal leukoencephalopathy. J Virol 75:12 (2001), 5672–5676.
66. Sahoo, M.K., Tan, S.K., Chen, S.F., Kapusinszky, B., Concepcion, K.R., Kjelson, L., et al. Limited Variation in BK Virus T-Cell Epitopes Revealed by Next-Generation Sequencing. J Clin Microbiol 53:10 (2015), 3226–3233.
67. Pastrana, D.V., Brennan, D.C., Cuburu, N., Storch, G.A., Viscidi, R.P., Randhawa, P.S., et al. Neutralization serotyping of BK polyomavirus infection in kidney transplant recipients. PLoS Pathog, 8(4), 2012 e1002650.
68. Duncavage, E.J., Zehnbauer, B.A., Pfeifer, J.D., Prevalence of Merkel cell polyomavirus in Merkel cell carcinoma. Mod Pathol 22:4 (2009), 516–521.
69. Iyer, J.G., Afanasiev, O.K., McClurkan, C., Paulson, K., Nagase, K., Jing, L., et al. Merkel cell polyomavirus-specific CD8(+) and CD4(+) T-cell responses identified in Merkel cell carcinomas and blood. Clin Cancer Res 17:21 (2011), 6671–6680.
70. Stakaityte, G., Wood, J.J., Knight, L.M., Abdul-Sada, H., Adzahar, N.S., Nwogu, N., et al. Merkel cell polyomavirus: molecular insights into the most recently discovered human tumour virus. Cancers (Basel) 6:3 (2014), 1267–1297.
71. Li, J., Wang, X., Diaz, J., Tsang, S.H., Buck, C.B., You, J., Merkel cell polyomavirus large T antigen disrupts host genomic integrity and inhibits cellular proliferation. J Virol 87:16 (2013), 9173–9188.
72. Pastrana, D.V., Tolstov, Y.L., Becker, J.C., Moore, P.S., Chang, Y., Buck, C.B., Quantitation of human seroresponsiveness to Merkel cell polyomavirus. PLoS Pathog, 5(9), 2009 e1000578.
73. Paulson, K.G., Carter, J.J., Johnson, L.G., Cahill, K.W., Iyer, J.G., Schrama, D., et al. Antibodies to merkel cell polyomavirus T antigen oncoproteins reflect tumor burden in Merkel cell carcinoma patients. Cancer Res 70:21 (2010), 8388–8397.
74. Laude, H.C., Jonchere, B., Maubec, E., Carlotti, A., Marinho, E., Couturaud, B., et al. Distinct Merkel cell polyomavirus molecular features in tumour and non tumour specimens from patients with Merkel cell carcinoma. PLoS Pathog, 6(8), 2010 e1001076.
75. Spurgeon, M.E., Lambert, P.F., Merkel cell polyomavirus: a newly discovered human virus with oncogenic potential. Virology 435:1 (2013), 118–130.
76. Bennett, S.M., Zhao, L., Bosard, C., Imperiale, M.J., Role of a nuclear localization signal on the minor capsid proteins VP2 and VP3 in BKPyV nuclear entry. Virology 474 (2015), 110–116.
77. Gan, D.D., Khalili, K., Interaction between JCV large T-antigen and beta-catenin. Oncogene 23:2 (2004), 483–490.
78. Hanson, C.A., Snover, D.C., Dehner, L.P., Fibroadenomatosis (fibroadenomatoid mastopathy): a benign breast lesion with composite pathologic features. Pathology 19:4 (1987), 393–396.
79. Lamba, S., Ravichandran, V., Major, E.O., Glial cell type-specific subcellular localization of 14-3-3 zeta: an implication for JCV tropism. Glia 57:9 (2009), 971–977.
80. Matsushita, M., Nonaka, D., Iwasaki, T., Kuwamoto, S., Murakami, I., Kato, M., et al. A new in situ hybridization and immunohistochemistry with a novel antibody to detect small T-antigen expressions of Merkel cell polyomavirus (MCPyV). Diagn Pathol, 9, 2014, 65.
81. Moriyama, T., Sorokin, A., BK virus (BKV): infection, propagation, quantitation, purification, labeling, and analysis of cell entry. Curr Protoc Cell Biol, 2009 Unit 26 2.
82. Nakamura, T., Sato, Y., Watanabe, D., Ito, H., Shimonohara, N., Tsuji, T., et al. Nuclear localization of Merkel cell polyomavirus large T antigen in Merkel cell carcinoma. Virology 398:2 (2010), 273–279.
83. Okada, Y., Endo, S., Takahashi, H., Sawa, H., Umemura, T., Nagashima, K., Distribution and function of JCV agnoprotein. J Neurovirol 7:4 (2001), 302–306.
84. Rinaldo, C.H., Traavik, T., Hey, A., The agnogene of the human polyomavirus BK is expressed. J Virol 72:7 (1998), 6233–6236.
85. Schowalter, R.M., Buck, C.B., The Merkel cell polyomavirus minor capsid protein. PLoS Pathog, 9(8), 2013 e1003558.
86. Tyagarajan, S.K., Frisque, R.J., Stability and function of JC virus large T antigen and T’ proteins are altered by mutation of their phosphorylated threonine 125 residues. J Virol 80:5 (2006), 2083–2091.
87. Lyngaa, R., Pedersen, N.W., Schrama, D., Thrue, C.A., Ibrani, D., Met, O., et al. T-cell responses to oncogenic merkel cell polyomavirus proteins distinguish patients with Merkel cell carcinoma from healthy donors. Clin Cancer Res 20:7 (2014), 1768–1778.
88. Miller, N.J., Church, C.D., Dong, L., Crispin, D., Fitzgibbon, M.P., Lachance, K., et al. Tumor-infiltrating Merkel Cell polyomavirus-specific T Cells are diverse and associated with improved patient survival. Cancer Immunol Res 5:2 (2017), 137–147.
89. Abend, J.R., Low, J.A., Imperiale, M.J., Global effects of BKV infection on gene expression in human primary kidney epithelial cells. Virology 397:1 (2010), 73–79.
90. Ariza, A., Mate, J.L., Isamat, M., Calatrava, A., Fernandez-Vasalo, A., Navas-Palacios, J.J., Overexpression of Ki-67 and cyclins A and B1 in JC virus-infected cells of progressive multifocal leukoencephalopathy. J Neuropathol Exp Neurol 57:3 (1998), 226–230.
91. Harms, P.W., Patel, R.M., Verhaegen, M.E., Giordano, T.J., Nash, K.T., Johnson, C.N., et al. Distinct gene expression profiles of viral- and nonviral-associated Merkel cell carcinoma revealed by transcriptome analysis. J Invest Dermatol 133:4 (2013), 936–945.
92. Radhakrishnan, S., Otte, J., Enam, S., Del Valle, L., Khalili, K., Gordon, J., JC virus-induced changes in cellular gene expression in primary human astrocytes. J Virol 77:19 (2003), 10638–10644.
93. Starrett, G.J., Marcelus, C., Cantalupo, P.G., Katz, J.P., Cheng, J., Akagi, K., et al. Merkel cell polyomavirus exhibits dominant control of the tumor genome and transcriptome in virus-associated merkel cell carcinoma. MBio, 8(1), 2017.
94. Arora, R., Shuda, M., Guastafierro, A., Feng, H., Toptan, T., Tolstov, Y., et al. Survivin is a therapeutic target in Merkel cell carcinoma. Sci Transl Med, 4(133), 2012, 133ra56.
95. Pina-Oviedo, S., Urbanska, K., Radhakrishnan, S., Sweet, T., Reiss, K., Khalili, K., et al. Effects of JC virus infection on anti-apoptotic protein survivin in progressive multifocal leukoencephalopathy. Am J Pathol 170:4 (2007), 1291–1304.
96. Gan, D.D., Reiss, K., Carrill, T., Del Valle, L., Croul, S., Giordano, A., et al. Involvement of Wnt signaling pathway in murine medulloblastoma induced by human neurotropic JC virus. Oncogene 20:35 (2001), 4864–4870.
97. Lill, C., Schneider, S., Ghanim, B., Brunner, M., Heiduschka, G., Loewe, R., et al. Expression of beta-catenin and cyclin D1 in Merkel cell carcinomas of the head and neck. Wien Klin Wochenschr 125:17–18 (2013), 501–507.
98. Ripple, M.J., Parker Struckhoff, A., Trillo-Tinoco, J., Li, L., Margolin, D.A., McGoey, R., et al. Activation of c-Myc and Cyclin D1 by JCV T-Antigen and beta-catenin in colon cancer. PLoS ONE, 9(9), 2014 e106257.
99. Pina-Oviedo, S., Khalili, K., Del Valle, L., Hypoxia inducible factor-1 alpha activation of the JCV promoter: role in the pathogenesis of progressive multifocal leukoencephalopathy. Acta Neuropathol 118:2 (2009), 235–247.
100. Signorini, L., Croci, M., Boldorini, R., Varella, R.B., Elia, F., Carluccio, S., et al. Interaction between human polyomavirus BK and hypoxia inducible factor-1 alpha. J Cell Physiol 231:6 (2016), 1343–1349.
101. Fernandez-Figueras, M.T., Puig, L., Musulen, E., Gilaberte, M., Lerma, E., Serrano, S., et al. Expression profiles associated with aggressive behavior in Merkel cell carcinoma. Mod Pathol 20:1 (2007), 90–101.
102. Kerkar, S.P., Wang, Z.F., Lasota, J., Park, T., Patel, K., Groh, E., et al. MAGE-A is more highly expressed than NY-ESO-1 in a systematic immunohistochemical analysis of 3668 cases. J Immunother 39:4 (2016), 181–187.
103. Goh, G., Walradt, T., Markarov, V., Blom, A., Riaz, N., Doumani, R., et al. Mutational landscape of MCPyV-positive and MCPyV-negative Merkel cell carcinomas with implications for immunotherapy. Oncotarget 7:3 (2016), 3403–3415.
104. Batinica, M., Akgul, B., Silling, S., Mauch, C., Zigrino, P., Correlation of Merkel cell polyomavirus positivity with PDGFRalpha mutations and survivin expression in Merkel cell carcinoma. J Dermatol Sci 79:1 (2015), 43–49.
105. White, M.K., Gordon, J., Berger, J.R., Khalili, K., Animal models for progressive multifocal leukoencephalopathy. J Cell Physiol 230:12 (2015), 2869–2874.
106. Butel, J.S., Patterns of polyomavirus SV40 infections and associated cancers in humans: a model. Curr Opin Virol 2:4 (2012), 508–514.
107. Lowe, D.B., Shearer, M.H., Aldrich, J.F., Winn, R.E., Jumper, C.A., Kennedy, R.C., Role of the innate immune response and tumor immunity associated with simian virus 40 large tumor antigen. J Virol 84:19 (2010), 10121–10130.
108. Mishra, R., Chen, A.T., Welsh, R.M., Szomolanyi-Tsuda, E., NK cells and gammadelta T cells mediate resistance to polyomavirus-induced tumors. PLoS Pathog, 6(5), 2010 e1000924.
109. Achim, C.L., Wiley, C.A., Expression of major histocompatibility complex antigens in the brains of patients with progressive multifocal leukoencephalopathy. J Neuropathol Exp Neurol 51:3 (1992), 257–263.
110. Dekeyser, M., Francois, H., Beaudreuil, S., Durrbach, A., Polyomavirus-specific cellular immunity: from BK-virus-specific cellular immunity to BK-virus-associated nephropathy?. Front Immunol, 6, 2015, 307.
111. Bauman, Y., Nachmani, D., Vitenshtein, A., Tsukerman, P., Drayman, N., Stern-Ginossar, N., et al. An identical miRNA of the human JC and BK polyoma viruses targets the stress-induced ligand ULBP3 to escape immune elimination. Cell Host Microbe 9:2 (2011), 93–102.
112. Bauman, Y., Drayman, N., Ben-Nun-Shaul, O., Vitenstein, A., Yamin, R., Ophir, Y., et al. Downregulation of the stress-induced ligand ULBP1 following SV40 infection confers viral evasion from NK cell cytotoxicity. Oncotarget 7:13 (2016), 15369–15381.
113. Womer, K.L., Huang, Y., Herren, H., Dibadj, K., Peng, R., Murawski, M., et al. Dendritic cell deficiency associated with development of BK viremia and nephropathy in renal transplant recipients. Transplantation 89:1 (2010), 115–123.
114. Womer, K.L., Peng, R., Patton, P.R., Murawski, M.R., Bucci, M., Kaleem, A., et al. The effects of renal transplantation on peripheral blood dendritic cells. Clin Transplant 19:5 (2005), 659–667.
115. Laniosz, V., Onajin, O., Sominidi-Damodaran, S., Meves, A., Gibson, L.E., Baum, C.L., Natural killer cell response is a predictor of good outcome in MCPyV+ Merkel cell carcinoma: a case series of 23 patients. J Am Acad Dermatol 77:1 (2017), 31–32.
116. Paulson, K.G., Tegeder, A., Willmes, C., Iyer, J.G., Afanasiev, O.K., Schrama, D., et al. Downregulation of MHC-I expression is prevalent but reversible in Merkel cell carcinoma. Cancer Immunol Res 2:11 (2014), 1071–1079.
117. Werchau, S., Toberer, F., Enk, A., Dammann, R., Helmbold, P., Merkel cell carcinoma induces lymphatic microvessel formation. J Am Acad Dermatol 67:2 (2012), 215–225.
118. Terui, H., Fujimura, T., Kakizaki, A., Furudate, S., Aiba, S., Merkel cell carcinoma with spontaneous regression: a case report and immunohistochemical study. Case Rep Dermatol 8:1 (2016), 52–58.
119. Knowles, W.A., Pipkin, P., Andrews, N., Vyse, A., Minor, P., Brown, D.W., et al. Population-based study of antibody to the human polyomaviruses BKV and JCV and the simian polyomavirus SV40. J Med Virol 71:1 (2003), 115–123.
120. Bohl, D.L., Brennan, D.C., Ryschkewitsch, C., Gaudreault-Keener, M., Major, E.O., Storch, G.A., BK virus antibody titers and intensity of infections after renal transplantation. J Clin Virol 43:2 (2008), 184–189.
121. Trampe, A.K., Hemmelmann, C., Stroet, A., Haghikia, A., Hellwig, K., Wiendl, H., et al. Anti-JC virus antibodies in a large German natalizumab-treated multiple sclerosis cohort. Neurology 78:22 (2012), 1736–1742.
122. Leuenberger, D., Andresen, P.A., Gosert, R., Binggeli, S., Strom, E.H., Bodaghi, S., et al. Human polyomavirus type 1 (BK virus) agnoprotein is abundantly expressed but immunologically ignored. Clin Vaccine Immunol 14:8 (2007), 959–968.
123. Viscidi, R.P., Clayman, B., Serological cross reactivity between polyomavirus capsids. Adv Exp Med Biol 577 (2006), 73–84.
124. Viscidi, R.P., Rollison, D.E., Viscidi, E., Clayman, B., Rubalcaba, E., Daniel, R., et al. Serological cross-reactivities between antibodies to simian virus 40, BK virus, and JC virus assessed by virus-like-particle-based enzyme immunoassays. Clin Diagn Lab Immunol 10:2 (2003), 278–285.
125. Carter, J.J., Paulson, K.G., Wipf, G.C., Miranda, D., Madeleine, M.M., Johnson, L.G., et al. Association of Merkel cell polyomavirus-specific antibodies with Merkel cell carcinoma. J Natl Cancer Inst 101:21 (2009), 1510–1522.
126. Lowe, D.B., Shearer, M.H., Jumper, C.A., Bright, R.K., Kennedy, R.C., Tumor immunity against a simian virus 40 oncoprotein requires CD8+ T lymphocytes in the effector immune phase. J Virol 84:2 (2010), 883–893.
127. Diotti, R.A., Capra, R., Moiola, L., Caputo, V., De Rossi, N., Sangalli, F., et al. Divergent trends of anti-JCPyV serum reactivity and neutralizing activity in multiple sclerosis (MS) patients during treatment with natalizumab. Viruses, 8(5), 2016.
128. Rossi, F., Li, X., Jacobson, L., Levine, A.J., Chen, Y., Palella, F.J., et al. BK virus capsid antibodies are associated with protection against subsequent development of PML in HIV-infected patients. Virology 485 (2015), 467–472.
129. Kable, K., Davies, C.D., O'Connell, P.J., Chapman, J.R., Nankivell, B.J., Clearance of BK virus nephropathy by combination antiviral therapy with intravenous immunoglobulin. Transplant Direct, 3(4), 2017, e142.
130. Randhawa, P.S., Schonder, K., Shapiro, R., Farasati, N., Huang, Y., Polyomavirus, B.K., neutralizing activity in human immunoglobulin preparations. Transplantation 89:12 (2010), 1462–1465.
131. Gheuens, S., Bord, E., Kesari, S., Simpson, D.M., Gandhi, R.T., Clifford, D.B., et al. Role of CD4+ and CD8+ T-cell responses against JC virus in the outcome of patients with progressive multifocal leukoencephalopathy (PML) and PML with immune reconstitution inflammatory syndrome. J Virol 85:14 (2011), 7256–7263.
132. Paulson, K.G., Iyer, J.G., Tegeder, A.R., Thibodeau, R., Schelter, J., Koba, S., et al. Transcriptome-wide studies of merkel cell carcinoma and validation of intratumoral CD8+ lymphocyte invasion as an independent predictor of survival. J Clin Oncol 29:12 (2011), 1539–1546.
133. Schaenman, J.M., Korin, Y., Sidwell, T., Kandarian, F., Harre, N., Gjertson, D., et al. Increased frequency of BK virus-specific polyfunctional CD8+ T cells predict successful control of BK viremia after kidney transplantation. Transplantation 101:6 (2017), 1479–1487.
134. Mancuso, R., Saresella, M., Hernis, A., Marventano, I., Ricci, C., Agostini, S., et al. JC virus detection and JC virus-specific immunity in natalizumab-treated multiple sclerosis patients. J Transl Med, 10, 2012, 248.
135. van Aalderen, M.C., Remmerswaal, E.B., Heutinck, K.M., ten Brinke, A., Pircher, H., van Lier, R.A., et al. Phenotypic and functional characterization of circulating polyomavirus BK VP1-specific CD8+ T cells in healthy adults. J Virol 87:18 (2013), 10263–10272.
136. Weist, B.J., Schmueck, M., Fuehrer, H., Sattler, A., Reinke, P., Babel, N., The role of CD4(+) T cells in BKV-specific T cell immunity. Med Microbiol Immunol 203:6 (2014), 395–408.
137. Aldrich, J.F., Lowe, D.B., Shearer, M.H., Winn, R.E., Jumper, C.A., Bright, R.K., et al. CD4+ T lymphocytes are critical mediators of tumor immunity to simian virus 40 large tumor antigen induced by vaccination with plasmid DNA. J Virol 85:14 (2011), 7216–7224.
138. Monaco, M.C., Major, E.O., Immune system involvement in the pathogenesis of JC virus induced PML: what is learned from studies of patients with underlying diseases and therapies as risk factors. Front Immunol, 6, 2015, 159.
139. Zhou, W., Sharma, M., Martinez, J., Srivastava, T., Diamond, D.J., Knowles, W., et al. Functional characterization of BK virus-specific CD4+ T cells with cytotoxic potential in seropositive adults. Viral Immunol 20:3 (2007), 379–388.
140. Cassler, N.M., Merrill, D., Bichakjian, C.K., Brownell, I., Merkel cell carcinoma therapeutic update. Curr Treat Options Oncol, 17(7), 2016, 36.
141. Kaufman, H.L., Russell, J., Hamid, O., Bhatia, S., Terheyden, P., D'Angelo, S.P., et al. Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial. Lancet Oncol 17:10 (2016), 1374–1385.
142. Nghiem, P.T., Bhatia, S., Lipson, E.J., Kudchadkar, R.R., Miller, N.J., Annamalai, L., et al. PD-1 blockade with pembrolizumab in advanced Merkel-cell Carcinoma. N Engl J Med 374:26 (2016), 2542–2552.
143. Bollard, C.M., Heslop, H.E., T cells for viral infections after allogeneic hematopoietic stem cell transplant. Blood 127:26 (2016), 3331–3340.
144. Papadopoulou, A., Gerdemann, U., Katari, U.L., Tzannou, I., Liu, H., Martinez, C., et al. Activity of broad-spectrum T cells as treatment for AdV, EBV, CMV, BKV, and HHV6 infections after HSCT. Sci Transl Med, 6(242), 2014, 242ra83.
145. Perez-Torres, D., Bertran-Pasarell, J., Santiago-Delpin, E., Gonzalez-Ramos, M., Medina-Mangual, S., Morales-Otero, L., et al. Factors and outcome in BK virus nephropathy in a Hispanic kidney transplant population. Transpl Infect Dis 12:1 (2010), 16–22.
146. Yoon, S.H., Cho, J.H., Jung, H.Y., Choi, J.Y., Park, S.H., Kim, Y.L., et al. Clinical impact of BK virus surveillance on outcomes in kidney transplant recipients. Transplant Proc 47:3 (2015), 660–665.
147. Dave, H., Luo, M., Blaney, J.W., Patel, S., Barese, C., Cruz, C.R., et al. Toward a rapid production of multivirus-specific T cells targeting BKV, adenovirus, CMV, and EBV from umbilical cord blood. Mol Ther Methods Clin Dev 5 (2017), 13–21.
148. Blyth, E., Clancy, L., Simms, R., Gaundar, S., O'Connell, P., Micklethwaite, K., et al. BK virus-specific T cells for use in cellular therapy show specificity to multiple antigens and polyfunctional cytokine responses. Transplantation 92:10 (2011), 1077–1084.
149. Mani, J., Jin, N., Schmitt, M., Cellular immunotherapy for patients with reactivation of JC and BK polyomaviruses after transplantation. Cytotherapy 16:10 (2014), 1325–1335.
150. Olson, A.L., Muftuoglu, M., Kaur, I., Li, L., Abueg, G., Chemaly, R., et al. Efficacy of third party BK virus (BKV) specific cytotoxic T-Lymphocytes generated By Ex Vivo expansion for the treatment of BKV infection in stem cell transplant recipients, a phase 2 trial. Blood, 128(22), 2016, 5.
151. Lamarche, C., Orio, J., Georges-Tobar, V., Pincez, T., Goupil, M., Dahmani, A., et al. Clinical-scale rapid autologous BK-virus specific T cell line generation from kidney transplant recipients with active viremia for adoptive immunotherapy. Transplantation, 2017, 10.1097/TP.0000000000001698.
152. Pavlovic, D., Patera, A.C., Nyberg, F., Gerber, M., Liu, M., Progressive multifocal leukoencephalopathy: current treatment options and future perspectives. Ther Adv Neurol Disord 8:6 (2015), 255–273.
153. Bloomgren, G., Richman, S., Hotermans, C., Subramanyam, M., Goelz, S., Natarajan, A., et al. Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N Engl J Med 366:20 (2012), 1870–1880.
154. Dong-Si, T., Gheuens, S., Gangadharan, A., Wenten, M., Philip, J., McIninch, J., et al. Predictors of survival and functional outcomes in natalizumab-associated progressive multifocal leukoencephalopathy. J Neurovirol 21:6 (2015), 637–644.
155. Sospedra, M., Schippling, S., Yousef, S., Jelcic, I., Bofill-Mas, S., Planas, R., et al. Treating progressive multifocal leukoencephalopathy with interleukin 7 and vaccination with JC virus capsid protein VP1. Clin Infect Dis 59:11 (2014), 1588–1592.
156. Balduzzi, A., Lucchini, G., Hirsch, H.H., Basso, S., Cioni, M., Rovelli, A., et al. Polyomavirus JC-targeted T-cell therapy for progressive multiple leukoencephalopathy in a hematopoietic cell transplantation recipient. Bone Marrow Transplant 46:7 (2011), 987–992.
157. Chapuis, A.G., Afanasiev, O.K., Iyer, J.G., Paulson, K.G., Parvathaneni, U., Hwang, J.H., et al. Regression of metastatic Merkel cell carcinoma following transfer of polyomavirus-specific T cells and therapies capable of re-inducing HLA class-I. Cancer Immunol Res 2:1 (2014), 27–36.
158. Bhatia, S., Burgess, M., Zhang, H., Lee, T., Klingemann, H., Soon-Shiong, P., et al. Adoptive cellular therapy (ACT) with allogeneic activated natural killer (aNK) cells in patients with advanced Merkel cell carcinoma (MCC): preliminary results of a phase II trial. Society for Immunotherapy of Cancer 31st Annual Meeting, 2016, 80–81.
159. Klebanoff, C.A., Rosenberg, S.A., Restifo, N.P., Prospects for gene-engineered T cell immunotherapy for solid cancers. Nat Med 22:1 (2016), 26–36.
160. Muranski, P., Restifo, N.P., Adoptive immunotherapy of cancer using CD4(+) T cells. Curr Opin Immunol 21:2 (2009), 200–208.
161. Muranski, P., Boni, A., Wrzesinski, C., Citrin, D.E., Rosenberg, S.A., Childs, R., et al. Increased intensity lymphodepletion and adoptive immunotherapy–how far can we go?. Nat Clin Pract Oncol 3:12 (2006), 668–681.